PMC7680184_01
Clinical history of the patient. Treatment and molecular testing is indicated in the figure.
OTT-13-11849-g0001.jpg
PMC7680184_01_OTT-13-11849-g0001.jpg
f0001
After 5 cycles of treatment, liver lesions were significantly decreased and radiograph revealed PR (Figure 1). Two cycles of maintenance therapy were conducted with capecitabine (1.5g bid d1-14) and bevacizumab (500mg d1 q3w) in May 2019 (Figure 1).
Tumor marker levels of the patient during treatment.
OTT-13-11849-g0002.jpg
PMC7680184_01_OTT-13-11849-g0002.jpg
f0002
CEA measurement decreased from 100ng/mL to 30ng/mL (Figure 2).
CT images of the patient before (A) and after (B and C) the regorafenib and nivolumab combination treatment.
OTT-13-11849-g0003.jpg
PMC7680184_01_OTT-13-11849-g0003.jpg
f0003
However, CT scanning revealed an abdominal disease progression in liver in late June (Figure 3). Until late August 2020, the patient's disease evaluation was PR with more than 12-month PFS (Figure 3).